Department of Medicine, Cooper University Hospital, Camden, NJ 08103, USA.
Division of Gastroenterology, Weill Cornell Medical Center, New York, NY 10065, USA.
Nutrients. 2024 Feb 26;16(5):658. doi: 10.3390/nu16050658.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a common cause of chronic liver disease globally, with prevalence rapidly increasing in parallel with rising rates of obesity and metabolic syndrome. MASLD is defined by the presence of excess fat in the liver, which may induce inflammatory changes and subsequent fibrosis in high-risk patients. Though MASLD occurs frequently, there is still no approved pharmacological treatment, and the mainstay of therapy remains lifestyle modification via dietary changes, enhancement of physical activity, and management of metabolic comorbidities. Most nutrition research and clinical guidance in this disease centers on the reduction in fructose and saturated fat in the diet, although the emerging literature suggests that protein supplementation is important and implicates muscle mass and sarcopenia in disease-related outcomes. This review will assess the current data on these topics, with the goal of defining best practices and identifying research gaps in care.
代谢功能障碍相关脂肪性肝病（MASLD）是一种常见的全球慢性肝病病因，其患病率随着肥胖症和代谢综合征发病率的上升而迅速增加。MASLD 的定义为肝脏内脂肪过多，这可能会在高危患者中引起炎症变化和随后的纤维化。尽管 MASLD 很常见，但仍然没有批准的药物治疗方法，治疗的主要方法仍然是通过饮食改变、增强身体活动和治疗代谢合并症来改变生活方式。大多数关于这种疾病的营养研究和临床指南都集中在减少饮食中的果糖和饱和脂肪上，尽管新出现的文献表明蛋白质补充很重要，并暗示肌肉质量和肌肉减少症与疾病相关的结果有关。这篇综述将评估这些主题的现有数据，旨在确定最佳实践并确定护理中的研究空白。
